Clinical trials: High Risk Group of Schizophrenia
Negative Symptoms of Schizophrenia
SPD489 as Adjunctive Treatment in Adults With Negative Symptoms of Schizophrenia
To assess the safety and efficacy of SPD489 low-dose and high-dose treatment groups to placebo when given as adjunctive therapy to antipsychotic medication in clinically stable adults with persistent predominant negative symptoms…
- Trial name
- NSS (NCT01234298)
- Testing
- SPD489 Low-Dose, SPD489 High-Dose
- Sponsor
- Shire
Clinical High Risk for Psychosis (CHR), Suicidal Ideation
Developing a Recovery-Oriented Suicide Prevention Program for Young People at Clinical High Risk for Psychosis
Young people at clinical high risk for psychosis are more likely to experience suicide thoughts than the general population, but there are few suicide prevention programs designed specifically for them.
- Conditions
- Clinical High Risk for Psychosis (CHR), Suicidal Ideation, Psychosis, Suicidal Behavior
- Trial name
- NCT07756567
- Testing
- Suicide Prevention Intervention, Standard Care (in control arm)
- Where
- 2 sites in United States
- Volunteers
- 108 people
- Sponsor
- University of California, San Diego
Schizophrenia, Bipolar Disorder
Indicated Prevention of Psychotic Disorders With Low-dose Lithium
This study investigates the neuroprotective properties of low-dose lithium in young individuals at ultra-high risk of developping a first psychotic episode.
- Conditions
- Schizophrenia, Bipolar Disorder, Psychotic Disorders
- Trial name
- NCT00202306
- Testing
- lithium carbonate
- Where
- Australia
- Volunteers
- 30 people
- Sponsor
- Melbourne Health
Schizophrenia
A Six-week, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center, Phase II Study
This is a prospective, six-week, randomized, double blind, placebo-controlled, multi-center study in patients with schizophrenia who are experiencing an acute exacerbation of psychosis.
- Trial name
- NCT00567710
- Testing
- BL - 1020, Risperidone
- Where
- United States
- Volunteers
- 360 people
- Sponsor
- BioLineRx, Ltd.
Schizophrenia
Extension Study To Evaluate The Long-Term Safety, Tolerability, And Efficacy Of Low And High Doses Of Bl-1020
A Six-Week, Randomized, Double-Blind, Parallel Group Extension Study To Evaluate The Long-Term Safety, Tolerability, And Efficacy Of Low And High Doses Of Bl-1020 Compared To Risperidone, In Schizophrenic Patients Previously…
- Trial name
- NCT00722176
- Testing
- BL-1020, BL-1020 10-30 mg, risperidone
- Where
- United States
- Volunteers
- 220 people
- Sponsor
- BioLineRx, Ltd.
ARMS, APS
Cognitive Behavioral Therapy for the Prevention of Paranoia in Adolescents at High Risk
The main objective of this study is to decrease the severity of symptoms and improve psycho-social functioning in youth at high risk of developing psychosis by providing a specialized Group-and-Family-based Cognitive Behavioral…
- Conditions
- ARMS, APS, Prodromal Symptoms
- Trial name
- NCT01923701
- Testing
- Cognitive Behavioral Therapy
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Weill Medical College of Cornell University
Schizophrenia
SPD489 Low Dose and High Dose Ranges When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia
The primary purpose of this study is to determine whether SPD489 low dose range (40, 80, or 100mg) and high dose range (120, 140, or 160mg) are effective in the treatment of Negative Symptoms.
- Trial name
- NCT01760889
- Testing
- SPD489 low dose range (40mg, 80mg, and 100mg), SPD489 high dose range (120mg, 140mg and 160mg)
- Where
- 4 sites in United States
- Volunteers
- 1 people
- Sponsor
- Shire
Psychosis
The Clinical and Socio-demographic Characteristics of Young People Aged 12 to 25 Consulting on Ambulatory Structures in the Seine Saint-Denis
A prospective study of the clinical and socio-demographic characteristics of young people aged 12 to 25 consulting on ambulatory structures in the Seine Saint-Denis.
- Trial name
- EPS-12-25 (NCT04365621)
- Testing
- we enrolled ultra-high risk of psychosis (UHR) patient to describe
- Where
- 5 sites in France
- Volunteers
- 900 people
- Sponsor
- Januel
High Risk Group of Schizophrenia
Early Identification and Predictive Parsing for High Risk Group of Schizophrenia
An accurate identification of individuals at ultra-high risk (UHR) based on psychometric tools to prospectively identify psychosis as early as possible is required for indicated preventive intervention.
- Trial name
- NCT05042739
- Testing
- CAARMS;SIPS; BSABS;
- Where
- China
- Volunteers
- 189 people, healthy volunteers welcome
- Sponsor
- Wuhan Mental Health Centre
Schizophrenia, Schizoaffective Disorder
High Dose of Quetiapine in Treating Subjects With Treatment Refractory Schizophrenia or Schizoaffective Disorder
This study will investigate the safety and efficacy of quetiapine in sub-optimally responding patients with DSM-IV schizophrenia using a double blind, randomized 12-week trial comparing oral doses of 1200 mg/d to 600 mg/d of…
- Trial name
- HDQ (NCT00297947)
- Testing
- quetiapine
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Manhattan Psychiatric Center
Schizophrenia
Study on Predictiors and Mechanism of Conversion to Psychosis in Individuals at Ultra-high Risk Group
Considering the complex pathological mechanism and the poor treatment outcomes of schizophrenia, early detection and intervention gradually become the key work for the foundational and clinical research in schizophrenia.
- Trial name
- NCT03965598
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Second Xiangya Hospital of Central South University
Prodromal Schizophrenia, Psychosis
Feasibility Trial of a Lifestyle Intervention for CHR-P
The present study will assess the feasibility and social validity of an adjunctive health promotion group for youth and clinical high risk for psychosis (CHR-P).
- Conditions
- Prodromal Schizophrenia, Psychosis, Psychological Disorder, Psychological Stress
- Trial name
- NCT05532683
- Testing
- Health Behaviors Group
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of California, Los Angeles